Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Jun;9(3):441-445.
doi: 10.21037/tlcr.2020.03.32.

Personalized post-surgical care?-possible strategies for NSCLCs with EGFR mutation

Kenichi Suda  1   2
Affiliations
Editorial

Personalized post-surgical care?-possible strategies for NSCLCs with EGFR mutation

Kenichi Suda. Transl Lung Cancer Res. 2020 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The author has completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tlcr.2020.03.32). KS reports grants and personal fees from Boehringer Ingelheim, personal fees from AstraZeneca, grants from Rain Therapeutics, outside the submitted work.

Comment on

References

    1. Hirsch FR, Suda K, Wiens J, et al. New and emerging targeted treatments in advanced non-small-cell lung cancer. Lancet 2016;388:1012-24. 10.1016/S0140-6736(16)31473-8 - DOI - PubMed
    1. Okami J, Shintani Y, Okumura M, et al. Demographics, Safety and Quality, and Prognostic Information in Both the Seventh and Eighth Editions of the TNM Classification in 18,973 Surgical Cases of the Japanese Joint Committee of Lung Cancer Registry Database in 2010. J Thorac Oncol 2019;14:212-22. - PubMed
    1. Ni J, Guo T, Li Y, et al. Patterns and risks of postoperative recurrence in completely resected EGFR-mutant non-small cell lung cancer: prognostic significance of routine immunohistochemical markers. Transl Lung Cancer Res 2019;8:967-78. 10.21037/tlcr.2019.12.02 - DOI - PMC - PubMed
    1. Kim H, Lee HJ, Hong H, et al. The prognostic implications of EGFR mutation and ALK rearrangement for the long-term outcomes of patients with resected lung adenocarcinomas. Thorac Cancer 2019;10:1619-27. 10.1111/1759-7714.13128 - DOI - PMC - PubMed
    1. Ito M, Miyata Y, Tsutani Y, et al. Positive EGFR mutation status is a risk of recurrence in pN0-1 lung adenocarcinoma when combined with pathological stage and histological subtype: A retrospective multi-center analysis. Lung Cancer 2020;141:107-13. 10.1016/j.lungcan.2020.01.018 - DOI - PubMed